万赛维治疗CMV视网膜炎的疗效如何？

The tablet is the L-valyl ester (prodrug) of ganciclovir, which is rapidly converted into ganciclovir by esterases in the small intestine and liver after oral administration. Ganciclovir is a synthetic 2’-deoxyguanosine monophosphate analog that inhibits herpesvirus replication in vitro and in vivo. Susceptible human viruses include human cytomegalovirus (HCMV), herpes simplex virus-1 and herpes simplex virus-2 (HSV-1, HSV-2), human herpesvirus-6, 7, 8 (HHV-6, 7, 8), Epstein-Barr virus, varicella-zoster virus (VZV), and hepatitis B virus.

Clinically, Vancevir tablets are suitable for the treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS). How effective is Vancevir in treating CMV retinitis?

The antiviral effect of Valcyte has been clinically demonstrated in the treatment of AIDS patients with newly diagnosed retinitis (clinical study WV15376). After 4 weeks of treatment with valganciclovir hydrochloride tablets, the detection rate of CMV virus decreased from 46% (32/69) to 7% (4/55).

Clinical studies of Valcyte in AIDS patients infected with CMV retinitis have shown that Valcyte and intravenous ganciclovir are equally effective in the induction treatment of CMV retinitis. In the study, patients with newly diagnosed CMV retinitis were randomly assigned to the Valcyte tablet group or the intravenous ganciclovir group for induction therapy. The proportion of patients with progression of CMV retinitis at week 4 was the same in both groups. After induction therapy, both groups of patients in the study continued to receive maintenance therapy with Valcyte tablets 900 mg per day. Among patients who received Valcyte tablets or intravenous ganciclovir induction therapy followed by Valcyte maintenance tablets, the mean (median) time from randomization to worsening of CMV retinitis was: 226 (160) days and 219 (125) days.